ES2643892T3 - Uso de micelas de proteínas de suero de leche para niños pequeños en riesgo de obesidad o diabetes - Google Patents

Uso de micelas de proteínas de suero de leche para niños pequeños en riesgo de obesidad o diabetes Download PDF

Info

Publication number
ES2643892T3
ES2643892T3 ES12775022.2T ES12775022T ES2643892T3 ES 2643892 T3 ES2643892 T3 ES 2643892T3 ES 12775022 T ES12775022 T ES 12775022T ES 2643892 T3 ES2643892 T3 ES 2643892T3
Authority
ES
Spain
Prior art keywords
diabetes
risk
whey protein
obesity
protein micelles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12775022.2T
Other languages
English (en)
Inventor
Catherine Mace
Lionel Jean René Bovetto
Etienne Pouteau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47045036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2643892(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2643892T3 publication Critical patent/ES2643892T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C21/00—Whey; Whey preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Uso de las micelas de proteínas de suero de leche para tratar y/o prevenir un trastorno relacionado con un incremento de la secreción de insulina y/o de la concentración plasmática de IGF-1 en un niño pequeño que tenga el riesgo de desarrollar obesidad o diabetes.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12775022.2T 2011-10-21 2012-10-19 Uso de micelas de proteínas de suero de leche para niños pequeños en riesgo de obesidad o diabetes Active ES2643892T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11186141 2011-10-21
EP11186141.5A EP2583562A1 (en) 2011-10-21 2011-10-21 Use of whey protein micelles for infants at risk of obesity or diabetes
PCT/EP2012/070718 WO2013057233A1 (en) 2011-10-21 2012-10-19 Use of whey protein micelles for infants at risk of obesity or diabetes

Publications (1)

Publication Number Publication Date
ES2643892T3 true ES2643892T3 (es) 2017-11-27

Family

ID=47045036

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12775022.2T Active ES2643892T3 (es) 2011-10-21 2012-10-19 Uso de micelas de proteínas de suero de leche para niños pequeños en riesgo de obesidad o diabetes

Country Status (11)

Country Link
US (1) US10028978B2 (es)
EP (2) EP2583562A1 (es)
CN (1) CN103906440B (es)
AU (1) AU2012324887B2 (es)
BR (1) BR112014009225A8 (es)
CL (1) CL2014000865A1 (es)
ES (1) ES2643892T3 (es)
MX (1) MX350866B (es)
PH (1) PH12014500611A1 (es)
RU (1) RU2616525C2 (es)
WO (1) WO2013057233A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
ES2693519T3 (es) * 2013-11-01 2018-12-12 N.V. Nutricia Composición lipídica para mejorar la composición corporal durante el crecimiento de recuperación
CN105764355A (zh) * 2013-11-25 2016-07-13 雀巢产品技术援助有限公司 乳基营养组合物与胃部不适
WO2015078974A1 (en) * 2013-11-29 2015-06-04 Nestec S.A. Infant nutrition for improvement in insulin sensitivity later in life
RU2638323C1 (ru) * 2013-11-29 2017-12-13 Нестек С.А. Применение питательных композиций с низким количеством белка
WO2015085555A1 (en) * 2013-12-12 2015-06-18 Nestec S.A. Array of age-tailored infant formula with optimum protein content and lactose content
WO2017064304A1 (en) 2015-10-15 2017-04-20 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
ES2987545T3 (es) 2016-12-09 2024-11-15 Nutricia Nv Composición nutricional para su uso en la mejora del rendimiento cognitivo y/o la prevención del deterioro cognitivo
EP3568028B1 (en) * 2017-01-11 2022-11-16 Société des Produits Nestlé S.A. Use of whey protein micelles and a source of casein for liquid spoonable nutritional compositions
CN110381964A (zh) * 2017-03-03 2019-10-25 森永乳业株式会社 Glp-1分泌促进剂和组合物
US20220233597A1 (en) * 2019-06-13 2022-07-28 Societe Des Produits Nestle S.A. Use of whey protein micelles for controlling postprandial glucose response
MX2022005462A (es) * 2019-11-08 2022-05-26 Abbott Lab Exosomas en polvo aislados de la leche bovina, composiciones alimenticias y metodos.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2683492B2 (ja) * 1993-09-07 1997-11-26 雪印乳業株式会社 ミセル状ホエー蛋白質、その溶液、その粉末およびミセル状ホエー蛋白質の製造法
US6303586B1 (en) * 1997-08-29 2001-10-16 The Ricex Company Supportive therapy for diabetes, hyperglycemia and hypoglycemia
ES2187115T3 (es) * 1999-01-20 2003-05-16 Nutricia Nv Preparado para lactantes.
DE19906379B4 (de) * 1999-02-16 2006-05-18 Huss, Manfred Herstellung eines aggregierten Molkenproteinprodukts
GB0302929D0 (en) * 2003-02-10 2003-03-12 Inst Of Child Health Nutrient composition
EP1648483B1 (en) * 2003-06-30 2008-06-04 Nestec S.A. Composition for treating and/or preventing insulin resistance
CA2538507A1 (en) * 2003-08-30 2005-03-10 Nestec S.A. Acid soluble proteins from micellar casein
MY153295A (en) * 2004-09-29 2015-01-29 Nestec Sa Nanoparticulated whey proteins
EP1839492B1 (en) 2006-03-27 2011-09-14 Nestec S.A. Whey protein micelles
MX2007007898A (es) 2004-12-27 2007-08-20 Nestec Sa Uso de formula para lactantes con contenido de proteina reducido.
CN101212911B (zh) * 2005-07-01 2012-12-05 努特里希亚公司 含水解的蛋白质的婴儿营养品
ES2537080T3 (es) 2005-12-23 2015-06-02 N.V. Nutricia Composición que comprende ácidos grasos poliinsaturados, proteínas y manganeso y/o molibdeno para mejorar la composición de membranas celulares
ATE472317T1 (de) * 2006-03-27 2010-07-15 Nestec Sa Kosmetische verwendung von molkeproteinmizellen
EP1932437A1 (en) 2006-12-15 2008-06-18 Nestec S.A. Infant formula
CN101438738A (zh) * 2007-11-23 2009-05-27 内蒙古蒙牛乳业（集团）股份有限公司 一种降血糖的酸奶及其生产方法
CN103005464B (zh) 2008-10-17 2015-01-07 雀巢产品技术援助有限公司 乳清蛋白组合物、方法及用途
AU2011224427B2 (en) * 2010-03-12 2014-07-31 Société des Produits Nestlé S.A. Compositions for masking the flavor of nutrients and methods for making same

Also Published As

Publication number Publication date
BR112014009225A2 (pt) 2017-06-13
EP2779846B1 (en) 2017-09-06
EP2779846A1 (en) 2014-09-24
US20140287056A1 (en) 2014-09-25
US10028978B2 (en) 2018-07-24
WO2013057233A1 (en) 2013-04-25
AU2012324887A1 (en) 2014-04-03
BR112014009225A8 (pt) 2017-06-20
RU2616525C2 (ru) 2017-04-17
MX2014004802A (es) 2015-12-03
AU2012324887B2 (en) 2015-10-29
EP2583562A1 (en) 2013-04-24
CL2014000865A1 (es) 2014-08-18
RU2014120428A (ru) 2015-11-27
CN103906440B (zh) 2016-09-21
CN103906440A (zh) 2014-07-02
PH12014500611A1 (en) 2020-10-19
MX350866B (es) 2017-09-22

Similar Documents

Publication Publication Date Title
ES2643892T3 (es) Uso de micelas de proteínas de suero de leche para niños pequeños en riesgo de obesidad o diabetes
CY1123515T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
CY1121895T1 (el) Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19
CY1123672T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
BR112019011228A2 (pt) compostos como agonistas do receptor de glp1/glucagon/gip trigonais peptídicos
AR087881A1 (es) Metodos para reducir los niveles de lipoproteina(a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9)
EA201592302A1 (ru) Способы снижения уровня остаточного холестерина и других фракций липопротеинов путем введения ингибитора пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9)
BR112016022465A2 (pt) agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4
PE20151765A1 (es) Formulas a base de hidrolizado de aminoacido y proteina con un sistema estable de emulsion
CR20130336A (es) Anticuerpo anti-pcsk9 y métodos de uso
BR112015027291A8 (pt) uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
BR112019011144A2 (pt) compostos como agonistas peptídicos de receptor de glp1/glucagon/gip
MX2018015089A (es) Combinacion de linagliptina y metformina.
BR112014009418A2 (pt) macrociclos peptidomiméticos
EA201590011A1 (ru) Пептидные аналоги эксендина-4
BR112014009785A8 (pt) método para tratar ou reduzir efp
CL2013003298A1 (es) Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo.
EP3008632A4 (en) COLOR SKETCHES IMAGE SEARCH
CL2013003144A1 (es) Composicion que comprende a) extracto de arroz fermentado con monascus purpureus, b) un acido graso omega, c) l-carnitina y uno o mas de los siguientes: d) al menos un policosanol, e) resveratrol, f) coenzima q10 y g) al menos una vitamina, util como anticolesterolemico y antitrigliceridemico y para aumentar el colesterol hdl.
CL2011001734A1 (es) Composición nutricional para infantes que comprende una fuente de proteína, una fuente de lípido y una fuente de carbohidrato, donde la fuente de lípido comprende ácido linoléico y ácido alfa-linolénico
BR112014009414A2 (pt) uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos
UA64465U (ru) Способ диагностики дисплазии соединительной ткани у больных с туберкулезом органов дыхания
Davidson Response to comment on: Davidson et al. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 2013; 36: 260–266
Barov et al. Chinese cinema and films: Organizational and lingvo-methodical bases in practice of teaching modern Chinese (First article)
Perera Special Editorial Note